Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-31
2011-11-29
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S406000, C548S139000, C548S362500
Reexamination Certificate
active
08067447
ABSTRACT:
Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, and/or AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, wherein (Ia) is heterocycle or heteroaryl; J, Ja, E, F, G, Ma, M, Q, Za and Z are as defined herein. Also provided are pharmaceutical compositions and methods of treating inflammatory- or immune-associated diseases and obesity and diabetes employing said compounds.
REFERENCES:
patent: 4882342 (1989-11-01), von der Saal et al.
patent: 4894386 (1990-01-01), Brown et al.
patent: 5599951 (1997-02-01), Plaquevent et al.
patent: 2006/0122250 (2006-06-01), Chaturvedula et al.
patent: WO 96/26918 (1996-09-01), None
patent: WO 03/104236 (2003-12-01), None
patent: WO 2004/099143 (2004-11-01), None
patent: WO 2005/056550 (2005-06-01), None
patent: WO 2006/076633 (2006-07-01), None
patent: WO 2006/138373 (2006-12-01), None
patent: WO 2007/062996 (2007-06-01), None
patent: WO2008/021926 (2008-02-01), None
patent: WO2008/057857 (2008-05-01), None
patent: WO2008/057859 (2008-05-01), None
patent: WO2008/057862 (2008-05-01), None
patent: WO 2008/070507 (2008-06-01), None
patent: WO 2008/079073 (2008-07-01), None
Morissette et al. “High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.” Advanced Drug Delivery Reviews 2004, 56, 275-300.
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry, pp. 217-218 (in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227).
Vippagunta, Sudha R. “Crystalline Solids.” Advanced Drug Delivery Reviews 48(2001): 3-26.
Ahluwalia, G.S. et al., “The Condensation of Aromatic Aldehydes with Malonanilic Acid and its Derivatives”, Journal of the Chemical Society, pp. 2059-2062 (1931).
Baldwin, Jr., A.S., “The transcription factor Nf-κB and human disease”, The Journal of Clinical Investigation, vol. 107, No. 1, pp. 3-6 (2001).
Burke, J.R., “Targeting IκB kinase for the treatment of inflammatory and other disorders”, Current Opinion in Drug Discovery & Development, vol. 6, No. 5, pp. 720-728 (2003).
Caldenhoven, E. et al., “Negative Cross-Talk between RelA and the Glucocorticoid Receptor: A Possible Mechanism for the Antiinflammatory Action of Glucocorticoids”, Molecular Endocrinology, vol. 9, No. 4, pp. 401-412 (1995).
Chakravarti, D. et al., “Role of CBP/P300 in nuclear receptor signalling”, Nature, vol. 383, pp. 99-103 (1996).
Diamond, M.I. et al., “Transcription Factor Interactions: Selectors of Positive or Negative Regulation from a Single DNA Element”, Science, vol. 249, pp. 1266-1272 (1990).
Firestein, G.S. et al., “Signal Transduction and Transcription Factors in Rheumatic Disease”, Arthritis & Rheumatism, vol. 42, No. 4, pp. 609-621 (1999).
Jonat, C. et al., “Antitumor Promotion and Antiinflammation: Down-Modulation of AP-1 (Fos/Jun) Activity by Glucocorticoid Hormone”, Cell, vol. 62, pp. 1189-1204 (1990).
Kamei, Y. et al., “A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors”, Cell, vol. 85, pp. 403-414 (1996).
Manning, A.M., et al., “Targeting JNK for Therapeutic Benefit: from Junk to Gold?”, Nature, vol. 2, pp. 554-565 (2003).
Miesfeld, R. et al., “Characterization of a steroid hormone receptor gene and mRNA in wild-type and mutant cells”, Nature, vol. 312, pp. 779-781 (1984).
Peltz, G., “Transcription factors in immune-mediated disease”, Current Opinion in Biotechnology, vol. 8, pp. 467-473 (1997).
Reichardt, H.M. et al., “DNA Binding of the Glucocorticoid Receptor is Not Essential for Survival”, Cell, vol. 93, pp. 531-541 (1998).
Reichardt, H.M. et al., “Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor”, The EMBO Journal, vol. 20, No. 24, pp. 7168-7173 (2001).
Schäcke, H. et al., “Dissociated non-steroidal glucocorticoid receptor modulators: an update on new compounds”, Expert Opin. Ther. Patents, vol. 18, No. 3, pp. 339-352 (2008).
Thoms, H. et al., “Fagaramide, a New Substance, Containing Nitrogen from the Root of Fagara xanthoxyloides Lam”, Berichte der Deutschen Chemischen Gesellschaft, vol. 44, pp. 3717-3730 (1912).
Weinberger, C. et al., “Domain structure of human glucocorticoid receptor and its relationship to the v-erb-Aoncogene product”, Nature, vol. 318, pp. 670-672 (1985).
Weinberger, C. et al., “Identification of Human Glucocorticoid Receptor Complementary DNA Clones by Epitope Selection”, Science, vol. 228, pp. 740-742 (1985).
Yang-Yen, H.-F. et al., “Transcriptional Interference between c-Jun and the Glucocorticoid Receptor: Mutual Inhibition of DNA Binding Due to Direct Protein-Protein Interaction”, Cell, vol. 62, pp. 1205-1215 (1990).
Dhar T. G. Murali
Gilmore John L.
Sheppeck James E.
Xiao Hai-Yun
Anderson Rebecca
Bristol--Myers Squibb Company
Otton Alicia L
Rodney Burton
LandOfFree
Modulators of glucocorticoid receptor, AP-1, and/or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of glucocorticoid receptor, AP-1, and/or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of glucocorticoid receptor, AP-1, and/or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4288108